BiotechTube
Home/Pipeline/Immunotherapy Platform Assets

Immunotherapy Platform Assets

Oncology (unspecified)

Pre-clinical (inferred)Active

Key Facts

Indication
Oncology (unspecified)
Phase
Pre-clinical (inferred)
Status
Active
Company
Theragene Pharmaceuticals

About Theragene Pharmaceuticals

Theragene Pharmaceuticals is a clinical-stage biotech developing novel therapies in oncology and cardiology via two distinct platforms: an immunotherapy platform designed to enhance the body's anti-tumor response and an AAV gene therapy platform for cardiovascular diseases. Operating with a unique US-Asia development model, the company aims to leverage regional strengths to accelerate and de-risk its programs. Its strategy centers on advancing its internal pipeline while seeking licensing and co-development partnerships to bring safe, effective treatments to market.

View full company profile

Therapeutic Areas

OncologyCardiovascular

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a